Navigation Links
Medinox Announces Clinical Results of Naproxen Prodrug
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE prodrug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the blood stream, it is converted rapidly and quantitatively to naproxen. It is being developed to provide therapeutic levels of naproxen while avoiding high local concentrations of naproxen in the GI tract, thereby reducing the local GI toxicity associated with conventional naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritics, including both rheumatoid arthritis (RA) and osteoarthritis (OA). The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced GI complications such as hemorrhage and perforation are directly responsible for about 20,000 deaths per year in the United States.

About Medinox, Inc.

Medinox, based in Carlsbad, CA, is a privately held biotechnology company, focused on developing novel therapeutic drugs for treating inflammation and septic shock. For more information about Medinox and its products, visit the company's website at www.medinox.com., or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc. at cslai@medinox.com.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.


'/>"/>
SOURCE Medinox, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Rebates, Inc. Announces the Launch of My HSA Rewards
2. Pro-cell Announces a Knock at the Door of Emerging Markets
3. March of Dimes Announces Nursing Scholarship Recipients
4. The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout
5. AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR
6. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
9. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
10. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
11. Medstrat Announces Integration of Echoes With MacPractices EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, ... co-exhibit with technology partners LG Business Solutions at ATARC Federal Mobile Computing ... Washington D.C., will provide education and examination into the mobility tools and technology ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... WAUKESHA, Wis. , March 27, 2017  A ... one of only four freestanding hospitals in the country ... in plastic and reconstructive surgery, concluded that the Surfacide ... effective and integral component in reducing bacterial pathogens not ... The findings were published at the American Burn Association,s ...
(Date:3/27/2017)... March 27, 2017 Medtec ... and more than 600 exhibitors from 70 countries ... and solutions that will advance the medical technology ... at the Messe Stuttgart, Stuttgart, Germany ... technology platform showcasing the key trends and insights ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
Breaking Medicine Technology: